Minsoo Kim is a Rheumatology/Immunology physician affiliated with University of Rochester Medicine. OpenAlex indexes 110 publications with 4,806 citations (h-index 42).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
550 1st Ave
New York, NY 100166402
Telephone
212-686-7500Registry record last updated 1 Aug 2014.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20258 payments
- GlaxoSmithKline, LLC.Program year20258 payments
- Novartis Pharmaceuticals CorporationProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
85.6%Corticosteroid38.8%Fluticasone Propionate60%Trelegy Ellipta15%Dulera13%Symbicort8%Breo Ellipta5%Part D<11 patientsHistamine-1 Receptor Antagonist23.6%Levocetirizine Dihydrochloride51%Azelastine Hcl49%Part D≥34 patients+ 3 more classes in this area
Dermatology
12.6%Interleukin-4 Receptor alpha Antagonist6.7%Dupixent Pen71%Dupixent Syringe30%Part D<11 patientsCorticosteroid5.9%Triamcinolone Acetonide100%Part D≥27 patientsMetabolism & gastrointestinal
1.8%Corticosteroid1.8%Prednisone100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
13 NIH research awards on record, funded 2007–2026 per NIH RePORTER. The latest:
- Monocyte-derived galectin-1 promotes tissue-resident memory T cell response
University of Rochester
FY2026$709,458R01AI187088 - T cell migration and cardiovascular toxicity in immunotherapy
University of Rochester
FY2026$683,310R01AI147362 - Monocytes support durable tissue-resident T cell immunity
Cornell University
FY2026$280,988P01AI102851
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Lisa Beck, MD
University of Rochester Medicine
Benzi Kluger, MD
University of Rochester Medicine
Darren Tabechian, MD
University of Rochester Medicine
Ayesa Mian, MD
University of Rochester Medicine
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”